JCRB1395 Kasumi-2
Cell information
Cell type：general cells (View Pricing Information)
| JCRB No. | JCRB1395 | Cell Name | Kasumi-2 |
|---|---|---|---|
| Profile | B cell precursor leukemia | Other Name | |
| Animal | human | Strain | |
| Genus | Homo | Species | sapiens |
| Sex | M | Age | 15 |
| Identity | available | Tissue for Primary Cancer | |
| Case history | acute lymphoblastic leukemia | Metastasis | |
| Tissue Metastasized | Genetics | t(1;19)(q23;p13), E2A-PBX fusion gene | |
| Life Span | infinite | Crisis PDL | |
| Morphology | lymphoblast-like | Character | |
| Classify | tumor | Established by | Asou, H. |
| Registered by | Asou, H. | Regulation for Distribution | |
| Comment | Year | 2009 | |
| Medium | RPMI1640 medium with 10% featal bovine serum. | Methods for Passages | dilution (split ratio 1:2 to 1:6) |
| Cell Number on Passage | 0.5-2.0 x 10^6 cells | Race | |
| CO2 Conc. | 5% | Tissue Sampling | blood |
| Tissue Type | tumor |
| Detection of virus genome fragment by Real-time PCR | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Detected DNA Virus | tested | Detected RNA Virus | tested | ||||||
| CMV | - | parvoB19 | - | HCV | - | HTLV-1 | - | ||
| EBV | - | HBV | - | HIV-1 | - | HTLV-2 | - | ||
| HHV6 | - | HTLV-1 | - | HIV-2 | - | HAV | - | ||
| HHV7 | - | HTLV-2 | - |
-/negative. +/positive. nt/not tested. (positive (+) does not immediately mean the production of infectious viral particles.) |
|||||
| BKV | - | HIV-1 | - | ||||||
| JCV | - | HIV-2 | - | ||||||
| ADV | - | HPV18 | - | ||||||
| Notes | |||||||||
| Research results by users. Click！ | |
|---|---|
| Pubmed id:32180206 |
Kasumi leukemia cell lines: characterization of tumor genomes with ethnic origin and scales of genomic alterations. Kasai F,Asou H,Ozawa M,Kobayashi K,Kuramitsu H,Satoh M,Kohara A,Kaneko Y,Kawamura M Hum Cell. 2020 Jul;33(3):868-876 |
LOT Information
| Cell No. | JCRB1395 | Cell Name | Kasumi-2 |
|---|---|---|---|
| LOT No. | 02152011 | Lot Specification | distribution |
| Medium | RPMI1640 medium(GIBCO) with 10% heat inactivated fetal bovine serum(SIGMA027K03911) | Temperature | 37 C |
| Cell Density at Seeding | 0.2-2.0x10^6 cells/ml | Methods for Passages | dilution(1/2-1/6) |
| Doubling Time | NT | Cell Number in Vial (cells/1ml) | 2.59x10^6 |
| Viability at cell freezing (%) | 96.3 | Antibiotics Used | free |
| Passage Number | P2* | PDL | NT |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | NT |
| Chromosome Mode | NT | Chromosome Information | NT |
| Surface Antigen | NT | DNA Profile (STR) | D5S818:11,12 D13S317:8,12,13 D7S820:11,12 D16S539:9,13 VWA:17,18 TH01:8,10 AM:X,Y TPOX:8,11 CSF1PO:10,11 |
| Adhesion | No | Exoteric Gene | NT |
| Medium for Freezing | Cell Banker BLC-1(Nihon Zenyaku Industries) | CO2 Conc. | 5 % |
| Viability immediately after thawing (%) | Additional information |
| Cell No. | JCRB1395 | Cell Name | Kasumi-2 |
|---|---|---|---|
| LOT No. | 01182019 | Lot Specification | distribution |
| Medium | RPMI 1640 medium with 10% heat-inactivated fetal bovine serum (FBS; Sigma Cat. # 172012) | Temperature | 37 C |
| Cell Density at Seeding | 0.3 - 1.1 x 10^5 cells/mL | Methods for Passages | Simple dilution (suspension culture). The size of cells is very small, therefore we recommend to centrifuge the cells at 1200 rpm or higher to collect all cells in vial at the thawing of cells. |
| Doubling Time | approx. 45 hrs. | Cell Number in Vial (cells/1ml) | 9.1 x 10^5 |
| Viability at cell freezing (%) | 87.4 | Antibiotics Used | free |
| Passage Number | Unknown (5 at bank) | PDL | |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | |
| Chromosome Mode | Chromosome Information | ||
| Surface Antigen | DNA Profile (STR) | ||
| Adhesion | No | Exoteric Gene | |
| Medium for Freezing | 10% DMSO, 20% FBS - RPMI1640 | CO2 Conc. | 5% |
| Viability immediately after thawing (%) | 81.9 | Additional information |